Sr 48692

In order to perform the experiments described here, we obtained the NTS1 antagonist SR48692 from R & D Systems, Inc. (Minneapolis, MN, USA). We synthesized the compounds NT(8-13), and our NTS1-derived pepducin series at the peptide synthesis facility of the Université de Sherbrooke (http://www.usherbrooke.ca/ips/en/platforms/psp/). This series consists of five main pepducins (NTS1-ICL1-PP-001 to NTS1-ICL1-PP-005), a non-palmitoylated control (NTS1-ICL1-NP-001), a pepducin with a scrambled peptide sequence (NTS1-ICL1-PP-SCR-001), as well as a TAMRA-labeled pepducin (NTS1-ICL1-FP-001). The specific peptide sequences are provided in Table 1. The protected amino acids and TentaGel R-RAM resins used in their synthesis were obtained from ChemImpex International (Wood Dale, IL, USA). All other chemicals and reagents involved in peptide and pepducin synthesis were obtained from Sigma-Aldrich (Oakville, ON, Canada) or Fisher Scientific (Montreal, QC, Canada). DMEM-F12, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), penicillin-streptomycin-glutamine, fetal bovine serum (FBS), gentamycin G418, phosphate-buffered solution (PBS), Hank's balanced salt solution (HBSS), trypsin-EDTA 0.25% were all obtained from Wisent (St. Bruno, QC, Canada).